Brief: Hls Therapeutics Announces Update On Health Canada Filings For Mycare And Trinomia

HLS Therapeutics

16/12/2020 11:35

Dec 16 (Reuters) - HLS Therapeutics Inc  HLS.TO :
    * HLS THERAPEUTICS ANNOUNCES UPDATE ON HEALTH CANADA FILINGS
FOR
MYCARE AND TRINOMIA
    * HLS THERAPEUTICS INC - HEALTH CANADA APPROVES MYCARE
PSYCHIATRY
LAB ASSAYS FOR USE IN DIAGNOSTIC LAB SETTINGS
    * HLS THERAPEUTICS INC - HEALTH CANADA ISSUED A NOTICE OF
DEFICIENCY FOR TRINOMIA
    * HLS THERAPEUTICS INC - MYCARE INSITE POINT-OF-CARE (POC)
DEVICE
IS UNDER REVIEW AND COULD BE APPROVED IN H1-2021
    * HLS THERAPEUTICS - WILL BE WORKING CLOSELY WITH LICENSOR
OF
TRINOMIA PRODUCT TO ASSESS PATHWAY REQUIRED TO ADDRESS
DEFICIENCY NOTED BY HEALTH CANADA
    * HLS THERAPEUTICS - PENDING SUBMISSION FOR TRINOMIA MAY
REQUIRE
ADDITIONAL SCIENTIFIC INFORMATION ON SAFETY AND EFFICACY TO
SUPPORT APPROVAL OF APPLICATION
    * HLS THERAPEUTICS INC - HEALTH CANADA NOTED THERE IS
ON-GOING
STUDY USING TRINOMIA
    * HLS THERAPEUTICS INC - IN INTERIM, FOCUS OF CARDIOVASCULAR
FRANCHISE WILL REMAIN FIRMLY ON SUCCESS OF VASCEPA IN CANADA
    * HLS THERAPEUTICS INC - HEALTH CANADA NOTED THAT "…A
REGULATORY
DECISION FOR TRINOMIA SHOULD AWAIT THESE STUDY RESULTS."

Source text for Eikon:  ID:nCNW9B0W9a 
Further company coverage:  HLS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))